A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)

NCT03611322 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Semaglutide, 0.25 mg
DRUG: Semaglutide, 0.5 mg
DRUG: Semaglutide, 1.0 mg
DEVICE: DV3372
DEVICE: PDS290 pen-injector

Sponsor

Novo Nordisk A/S